1. Home
  2. RVYL vs CVKD Comparison

RVYL vs CVKD Comparison

Compare RVYL & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ryvyl Inc.

RVYL

Ryvyl Inc.

HOLD

Current Price

$5.56

Market Cap

9.3M

ML Signal

HOLD

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$4.28

Market Cap

9.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVYL
CVKD
Founded
2007
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.3M
9.9M
IPO Year
2008
2022

Fundamental Metrics

Financial Performance
Metric
RVYL
CVKD
Price
$5.56
$4.28
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
N/A
$13.00
AVG Volume (30 Days)
46.4K
41.9K
Earning Date
05-19-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
60.34
23.94
EPS
N/A
N/A
Revenue
$55,998,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$297.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$4.21
52 Week High
$8.55
$17.50

Technical Indicators

Market Signals
Indicator
RVYL
CVKD
Relative Strength Index (RSI) 49.95 29.91
Support Level $5.31 $4.21
Resistance Level $6.15 $14.21
Average True Range (ATR) 0.60 0.66
MACD 0.01 -0.18
Stochastic Oscillator 60.37 1.74

Price Performance

Historical Comparison
RVYL
CVKD

About RVYL Ryvyl Inc.

Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Share on Social Networks: